Mode
Text Size
Log in / Sign up
N/A N=96 Diagnostic

The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury

Acute Kidney Failure

Enrolled (actual)
96
Serious AEs
0.0%
Results posted
Jul 2023
Primary outcome: Primary: Progression to Stage 3 AKI — 23 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Furosemide (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Chicago
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Progression to Stage 3 AKI
23
PRIMARY
Receipt of Renal Replacement Therapy (RRT)
10
PRIMARY
Death
16
SECONDARY
Length of Intensive Care Unit (ICU) Stay
9.15
SECONDARY
Length of Hospital Stay
17.29

Summary

The primary objective is to safely determine if the investigators can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled the investigators will draw blood and urine for novel and standard biomarkers. The investigators are attempting to determine if these biomarkers can forecast the course of AKI (need for dialysis, death and renal recovery). The investigators seek to determine how well physicians caring for those with AKI can predict the clinical course compared to these novel biomarkers of AKI and if there is an association between clinical course and 3 year patient outcomes.

Eligibility Criteria

Inclusion Criteria

  • 18 yrs or older
  • increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater than or equal to 150% from baseline or sustained oliguria (UOP < 0.5 cc/kg/hr for 6 hours with the last 48hours)
  • written informed consent
  • patients with an indwelling bladder catheter

Exclusion Criteria

  • Voluntary refusal
  • Patients with advanced chronic kidney disease - as defined by a baseline glomerular filtration rate (GFR) < 30 ml/min (MDRD)
  • history of renal transplant
  • Pregnant patients
  • Allergy / Sensitivity to Loop diuretics (furosemide)
  • Pre-renal AKI
  • defined by a Fractional Excretion of Sodium (FENa) of < 1% and no urinary casts
  • under-resuscitated as per the treating clinical team
  • active bleed
  • Post renal AKI
  • evidence of hydro-ureter
  • clinical scenario wherein obstruction is considered a likely possibility
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01275729). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search